1. Home
  2. ANNX vs FSBW Comparison

ANNX vs FSBW Comparison

Compare ANNX & FSBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANNX
  • FSBW
  • Stock Information
  • Founded
  • ANNX 2011
  • FSBW 1936
  • Country
  • ANNX United States
  • FSBW United States
  • Employees
  • ANNX N/A
  • FSBW N/A
  • Industry
  • ANNX Biotechnology: Pharmaceutical Preparations
  • FSBW Banks
  • Sector
  • ANNX Health Care
  • FSBW Finance
  • Exchange
  • ANNX Nasdaq
  • FSBW Nasdaq
  • Market Cap
  • ANNX 334.1M
  • FSBW 308.6M
  • IPO Year
  • ANNX 2020
  • FSBW 2012
  • Fundamental
  • Price
  • ANNX $3.00
  • FSBW $39.99
  • Analyst Decision
  • ANNX Strong Buy
  • FSBW Hold
  • Analyst Count
  • ANNX 4
  • FSBW 1
  • Target Price
  • ANNX $13.00
  • FSBW $44.00
  • AVG Volume (30 Days)
  • ANNX 2.1M
  • FSBW 13.7K
  • Earning Date
  • ANNX 11-13-2025
  • FSBW 10-21-2025
  • Dividend Yield
  • ANNX N/A
  • FSBW 2.83%
  • EPS Growth
  • ANNX N/A
  • FSBW N/A
  • EPS
  • ANNX N/A
  • FSBW 4.08
  • Revenue
  • ANNX N/A
  • FSBW $140,954,000.00
  • Revenue This Year
  • ANNX N/A
  • FSBW $9.62
  • Revenue Next Year
  • ANNX N/A
  • FSBW $5.35
  • P/E Ratio
  • ANNX N/A
  • FSBW $9.71
  • Revenue Growth
  • ANNX N/A
  • FSBW 1.07
  • 52 Week Low
  • ANNX $1.29
  • FSBW $34.61
  • 52 Week High
  • ANNX $7.74
  • FSBW $49.15
  • Technical
  • Relative Strength Index (RSI)
  • ANNX 51.42
  • FSBW 53.27
  • Support Level
  • ANNX $2.87
  • FSBW $38.35
  • Resistance Level
  • ANNX $3.36
  • FSBW $39.18
  • Average True Range (ATR)
  • ANNX 0.21
  • FSBW 0.77
  • MACD
  • ANNX -0.03
  • FSBW 0.06
  • Stochastic Oscillator
  • ANNX 25.24
  • FSBW 80.49

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About FSBW FS Bancorp Inc.

FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.

Share on Social Networks: